Home / Pharmaceutical / The Pharmaceutical Market: Germany

The Pharmaceutical Market: Germany

Published: Nov 2014 | No Of Pages: 125 | Published By: Espicom

Product Synopsis

 
OVERVIEW OF THE PHARMACEUTICAL MARKET IN GERMANY
 
While the Arzneimittelmarkt-Neuordnungsgesetz ( AMNOG ) legislation will compress drug companies' revenue-earning opportunities in Germany, we believe the government's decision to make the final reimbursement prices of medicines sold in the country publicly available, and the use of reference pricing across the region, will also lead to price reductions in other countries, providing an aggregation of pricing pressures on companies operating throughout Europe . For its part, the German pharmaceutical market is expected to decline in value by a compound annual growth rate (CAGR) of 0.5% through to 2016, as expressed in local currency terms, or by 3.4% in US dollars.
 
Headline Expenditure Projections
  • Pharmaceuticals: EUR39.67bn (US$55.15bn) in 2011 to EUR38.65bn (US$49.08bn) in 2012; -2.6% in local currency terms and -11.0% in US dollar terms. Forecast unchangedfromQ4 12.
  • Healthcare: EUR272.67bn (US$379.01bn) in 2011 to EUR279.09bn (US$354.44bn) in 2012; +2.4% in local currency terms and -6.5% in US dollar terms. Forecast unchangedfromQ4 12.
  • Medicaldevices: EUR14.97bn (US$20.81bn) in 2011 to EUR15.62bn (US$19.83bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast unchangedfromQ4 12.
Risk/RewardRating
 
In our PharmaceuticalRisk/RewardRatings (RRRs) for Q113, Germany remains ranked third in Western Europe, behind Switzerland and the UK. Despite the tough pricing and reimbursement conditions and the effects of patent expirations, Germany remains one of the largest global pharmaceutical markets, which will continue to prop up its rewards score. Its risks are also expected to remain above the regional average, which is illustrative of the favourable operating environment.
 
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT9
Political11
Economic12
Business Environment13
Industry Forecast14
Pharmaceutical Market Forecast14
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Denmark 2010-2018)15
 
Healthcare Market Forecast16
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Denmark 2010-2018)17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Denmark 2010-2018)18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Denmark 2010-2018)18
 
Macroeconomic Forecasts19
Economic Analysis19
 
Table: GDP By Expenditure (Denmark 2011-2018)25
 
Industry Risk Reward Ratings26
Western Europe Risk/Reward Ratings26
Denmark Risk/Reward Ratings32
Rewards32
Risks33
Market Overview34
Industry Trends And Developments36
Epidemiology36
Regulatory Development38
Pricing Regime40
Reimbursement Regime41
 
Table: Expenditure On Reimbursed Medicines (DKRmn)43
 
Competitive Landscape44
 
Table: LIF Member Companies46
 
Demographic Forecast48
Demographic Outlook48
 
Table: Denmark's Population By Age Group, 1990-2020 ('000)49
Table: Denmark's Population By Age Group, 1990-2020 (% of total)50
Table: Denmark's Key Population Ratios, 1990-202051
Table: Denmark's Rural And Urban Population, 1990-202051
 
Glossary52
Methodology54
Pharmaceutical Expenditure Forecast Model54
Healthcare Expenditure Forecast Model54
Notes On Methodology55
Risk/Reward Ratings Methodology56
Ratings Overview57
 
Table: Pharmaceutical Risk/Reward Ratings Indicators57
 
Indicator Weightings58
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +